Table 1.
Baseline characteristics of the recruited NAION patitents.
| Total | Control group | PRP group | p | |
|---|---|---|---|---|
| Study subjects (eyes) | 25 | 13 | 12 | |
| Male (n, %) | 21 (84%) | 10 (76.9%) | 11 (91.7%) | 0.647c |
| Age of onset (mean ± SD, years) | 50.84 ± 9.64 | 51.08 ± 11.44 | 50.58 ± 7.74 | 0.806a |
| BMI (mean ± SD, kg/m2) | 24.56 ± 1.84 | 24.62 ± 1.32 | 24.48 ± 2.35 | 0.605a |
| Unilateral eye onset (n, %) | 24 (96%) | 12 (92.3%) | 12 (100%) | 0.999d |
| History of NAION (n, %) | 12 (48%) | 5 (38.5%) | 7 (58.3%) | 0.320b |
| Presence of small cup-to-disc ratio or a crowded optic nerve (n, %) | 12 (48%) | 10 (76.9%) | 2 (16.7%) | 0.003 b |
| Type of visual field defect (n, %) | ||||
| Diffuse defect | 15 (60%) | 8 (61.5%) | 7 (58.3%) | 0.999c |
| Quadrant defect | 10 (40%) | 5 (38.5%) | 5 (41.7%) | |
| Central or paracentral scotoma | 0 | 0 | 0 | |
| Onset to PRP window (median, IQR, days) | — | — | 25.5 (18.8, 37) | — |
| Systemic diseases | ||||
| Hypertension (n, %) | 11 (44%) | 6 (46.2%) | 5 (41.7%) | 0.821b |
| Diabetes mellitus (n, %) | 12 (48%) | 6 (46.2%) | 6 (50%) | 0.848b |
| Hyperlipidemia (n, %) | 10 (40%) | 3 (23.1%) | 7 (58.3%) | 0.165c |
| Hyperhomocysteinemia (n, %) | 2 (8%) | 0 | 2 (16.7%) | 0.220d |
| Nocturnal hypotension (n, %) | 4 (16%) | 3 (23.1%) | 1 (8.3%) | 0.647c |
| Obstructive sleep apnea (n, %) | 10 (40%) | 6 (46.2%) | 4 (33.3%) | 0.806c |
| History of ischemic heart disease (n, %) | 1 (4%) | 1 (0.7%) | 0 | 0.999d |
| History of stroke (n, %) | 0 | 0 | 0 | — |
| History of malignant tumor (n, %) | 0 | 0 | 0 | — |
NAION, nonarteritic anterior ischemic optic neuropathy; PRP, platelet rich plasma; BMI, body mass index; n, number; SD, standard deviation; IQR, interquartile range.Bold: p < 0.05.
a
Mann–Whitney test.
b
Chi-square test.
c
Correct chi-square test.
d
Fisher’s exact test.